A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Trial Profile

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs CB 839 (Primary) ; Nivolumab
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 15 Jan 2018 The protocol has been amended to remove the Monotherapy arm from the treatment table i.e. the CB-839 as Monotherapy for Melanoma.
    • 15 Jan 2018 Planned number of patients changed from 242 to 299.
    • 07 Nov 2017 Results presented in a Calithera Biosciences Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top